Corporate ActionJul 30, 2026, 04:09 PM
VYNE Therapeutics Exchanges 133,290 Shares for Pre-Funded Warrants
AI Summary
VYNE Therapeutics Inc. entered into an exchange agreement on July 29, 2026, with an existing stockholder. Under the agreement, the stockholder exchanged 133,290 shares of common stock for pre-funded warrants to purchase an aggregate of 133,290 shares of common stock at an exercise price of $0.0001 per share. These warrants are immediately exercisable, subject to a beneficial ownership limitation of 9.99%, which can be increased to 19.99% with 61 days' notice. Following the exchange, the company has 2,669,788 shares of common stock outstanding and pre-funded warrants to purchase 25,914,530 shares of common stock outstanding.
Key Highlights
- VYNE Therapeutics exchanged 133,290 common shares for pre-funded warrants.
- Pre-funded warrants allow purchase of 133,290 shares at an exercise price of $0.0001 per share.
- Warrants are immediately exercisable upon issuance.
- Beneficial ownership limitation set at 9.99%, adjustable up to 19.99% with 61 days' notice.
- The exchange closed on July 29, 2026.
- Post-exchange, 2,669,788 common shares are outstanding.
- Post-exchange, pre-funded warrants to purchase 25,914,530 shares are outstanding.
Price Impact
More from VYNE